GERN
GERON CORP
NASDAQ · Healthcare · Biotechnology · US
$1.08
+16.13%Nov 4, 2026, 14:56 UTC
GERON CORP reported break-even earnings per share for the third quarter, compared with a loss of $0.03 per share a year earlier.
Source:Nov 4, 2026, 14:00 UTC
GERON CORP announced that six abstracts on RYTELO (imetelstat) were accepted for poster presentation at the 68th American Society of Hematology Annual Meeting.
Source:Nov 4, 2026, 12:03 UTC
GERON CORP reported RYTELO net product revenue of $60.1 million in the third quarter of 2026, up 5% from the second quarter of 2026.
Source:Oct 28, 2026, 17:55 UTC
GERON CORP shares plunged on Wednesday.
Source:Oct 28, 2026, 17:55 UTC
GERON CORP halted its late-stage cancer program and shifted its focus to commercial growth.
Source:Oct 28, 2026, 12:00 UTC
GERON CORP announced that it will discontinue the Phase 3 IMpactMF trial evaluating imetelstat in patients with JAK inhibitor relapsed/refractory myelofibrosis, following a recommendation from the independent GERON CORP.
Source:Oct 21, 2026, 12:00 UTC
GERON CORP announced that it will release its third-quarter 2026 financial results and business highlights before the market opens on November 4, 2026, and host a conference call and webcast at 8:00 a.m. Eastern Time.
Source:Oct 19, 2026, 20:01 UTC
GERON CORP granted stock options to three newly hired employees to purchase an aggregate of 570,000 common shares as an inducement to accept employment.
Source:Oct 12, 2026, 12:03 UTC
GERON CORP announced two oral presentations and one poster presentation on imetelstat in patients with lower-risk myelodysplastic syndromes at hematology meetings in Japan and the German-speaking region.
Source:Sep 18, 2026, 20:01 UTC
Geron Corporation granted stock options to purchase an aggregate of 821,250 shares of common stock to nine newly hired employees as an inducement to their acceptance of employment, effective September 17, 2026.
Source:Sep 14, 2026, 18:16 UTC
Kahn Swick & Foti, LLC commenced an investigation into the officers and directors of Geron Corporation.
Aug 5, 2026, 11:00 UTC
Geron Corporation reported second quarter 2026 financial results, with RYTELO net product revenue of $57.5 million, an 11% increase from the first quarter of 2026, and cash and marketable securities of $327 million at the end of the quarter.
Jul 13, 2026, 12:00 UTC
Geron Corporation appointed Chinmaya Rath as Chief Business Officer.
Jul 1, 2026, 14:11 UTC
Geron Corporation reported Q1'26 Rytelo revenues of $51.8 million, up 8% sequentially, with two consecutive quarters of demand growth.
Source:Jun 1, 2026, 20:05 UTC
Fulcrum Therapeutics discontinued its pociredir program in sickle cell disease following FDA feedback about secondary malignancies observed with Tazverik and its global withdrawal.
Jun 1, 2026, 18:06 UTC
Replimune aligned with the FDA on plans to resubmit its Biologics License Application for RP1 plus Opdivo in advanced melanoma.
Source:Jun 1, 2026, 18:00 UTC
Merck's calderasib plus Keytruda received FDA Breakthrough Therapy designation for newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.
Source:Jun 1, 2026, 16:32 UTC
Iovance Biotherapeutics obtained FDA clearance of an Investigational New Drug application for IOV-5001, extending its cell therapy platform into solid tumors.
Source:Jun 1, 2026, 12:30 UTC
PolyPid completed a New Drug Application submission to the FDA for D-PLEX100.
Source:Jun 1, 2026, 11:00 UTC
Kamada Ltd. received FDA approval for its new in-house Rabies Virus Neutralization Testing Laboratory.
Source:Jun 1, 2026, 09:53 UTC
Geron received FDA approval for RYTELO in low- to intermediate-1 risk MDS.
Source: